Beijing Konruns Pharmaceutical (603590.SH): The KC1101 project has received a clinical trial notice.

date
15:34 19/11/2026
avatar
GMT Eight
Beijing Konruns Pharmaceutical (603590.SH) announced that recently, the company received a clinical trial notice approved and issued by the National Medical Products Administration for KC1101 tablets, a Class 1 innovative chemical drug. KC1101 is a TACC3-selective small molecule inhibitor independently developed by the company, intended for the treatment of advanced recurrent or metastatic solid tumors.
Beijing Konruns Pharmaceutical (603590.SH) announced that the company recently received a clinical trial notice approved and issued by the National Medical Products Administration for KC1101 tablets, a Class 1 innovative chemical drug. KC1101 is a TACC3-selective small molecule inhibitor independently developed by the company, intended for the treatment of advanced recurrent or metastatic solid tumors.